(Q45861335)

17 December 2017

editorial

0 references

title

Computational modelling and inhibitor risk: predicting the future? (English)

1 reference

17 December 2017

author name string

D P Hart

series ordinal

1

1 reference

17 December 2017

publication date

7 January 2014

1 reference

17 December 2017

published in

Haemophilia

1 reference

17 December 2017

volume

20

1 reference

17 December 2017

issue

2

1 reference

17 December 2017

page(s)

155-157

1 reference

17 December 2017

HLA class II genotype and factor VIII inhibitors in mild haemophilia A patients with an Arg593 to Cys mutation.

cites work

1 reference

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.

21 January 2018

1 reference

CD4+ T-cell clones specific for wild-type factor VIII: a molecular mechanism responsible for a higher incidence of inhibitor formation in mild/moderate hemophilia A.

21 January 2018

1 reference

T-cell responses in two unrelated hemophilia A inhibitor subjects include an epitope at the factor VIII R593C missense site.

21 January 2018

1 reference

State of the art and challenges in sequence based T-cell epitope prediction

21 January 2018

1 reference

Structure of the human class I histocompatibility antigen, HLA-A2

21 January 2018

1 reference

Evaluation of MHC class I peptide binding prediction servers: applications for vaccine research

21 January 2018

1 reference

T-cell epitope vaccine design by immunoinformatics

21 January 2018

1 reference

T-cell epitope prediction: rescaling can mask biological variation between MHC molecules

21 January 2018

1 reference

Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1.

21 January 2018

1 reference

Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide

21 January 2018

1 reference

NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction

21 January 2018

1 reference

Polymorphisms in the F8 gene and MHC-II variants as risk factors for the development of inhibitory anti-factor VIII antibodies during the treatment of hemophilia a: a computational assessment

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/HAE.12332

1 reference

17 December 2017

1 reference

17 December 2017